Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study

Schizophrenia Bulletin

Volumn 41, Issue 2, 2015, Pages 449-459

  Buckley, Peter F ^a   Schooler, Nina R ^b,c   Goff, Donald C ^d   Hsiao, John ^e   Kopelowicz, Alexander ^f   Lauriello, John ^g   Manschreck, Theo ^h   Mendelowitz, Alan J ^c   Miller, Del D ⁱ   Severe, Joanne B ^e   Wilson, Daniel R ^j   Ames, Donna ^f   Bustillo, Juan ^k   Mintz, Jim ^l   Kane, John M ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g University of Missouri   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

Clinical trial design; Negative symptoms; Psychotic symptoms; Relapse prevention; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; HYPNOTIC AGENT; ILOPERIDONE; LONG ACTING DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG; ZIPRASIDONE; DELAYED RELEASE FORMULATION;

ADULT; ANOREXIA; ARTICLE; BLURRED VISION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART ARREST; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; HOSPITAL READMISSION; INJECTION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; PSYCHOTIC DISORDERS; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA;

EID: 84926329539     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu067     Document Type: Article

References (39)

1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts"
2. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122:1-23.
3. Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):19-23.
4. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115-1124.
5. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216-226.
6. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83-92.
7. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192-213.
8. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568-575.
9. Kishimoto T, Agarwal V, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2011;143:1-14.
10. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirrorimage studies. J Clin Psychiatry. 2013;74:957-965.
11. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36:1283-1294.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed: DSM-IV-TR. Washington, DC: American Psychiatric Press; 2000.
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10:799-812.
14. Guy W. Clinical Global Impressions (CGI). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:217-222.
15. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
16. Rapaport MH, Bazzetta J, McAdams LA, Patterson T, Jeste DV. Validation of the scale of functioning in older outpatients with schizophrenia. Am J Geriat Psychiatry. 1996;4:218-28.
17. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:534-537.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
20. Burke MA, McEvoy JP, Ritchie JC. A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biol Psychiatry. 1994;35:32-35.
21. Guzik LH, Erickson ZE, Mena SJ, Pierre JM, Ames D. Measuring patients' subjective experiences taking antipsychotic medications using the Novel Antipsychotic Medication Experience Scale (NAMES): a preliminary Analysis. International Congress of Schizophrenia Research; March 28-April 1; San Diego, CA. Schizophr. Bull. 2009; 35 (supplement 1): 36, ID: 551878.
22. Csernansky JG, Mahmoud R, Brenner R; Risperidone- USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
23. Liu C, Cao D, Chen P, Zagar T. RANDOM and REPEATED statements: how to use them to model the covariance structure in Proc Mixed. MidWestern SAS Users Group, Proceedings 2007. Paper S02-2007. www.mwsug.org/proceedings/2007/ stats/MWSUG-2007-S02.pdf. Accessed May 7, 2014.
24. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983-997.
25. Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry. 2011;168:770-775.
26. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmaticexplanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464-475.
27. Rosenheck RA, Krystal JH, Lew R, et al.; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-851.
28. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry. 2010;7:23-31.
29. Novice D, Ascher-Swanum H, Bertsch J, Detke H, McDonnell D, Hato JM. Risk of relapse and hospitalization in the 2-year open-label treatment of outpatients with schizophrenia randomized to olanzapine long acting injection or oral olanzapine. Presentation at the 3rd Biennial Conference of the Schizophrenia International Research Society; April 2012; Florence, Italy.
30. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35:2367-2377.
31. de Arce Cordón R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Eur Arch Psychiatry Clin Neurosci. 2012;262:139-149.
32. Smeraldi E, Cavallaro R, Folnegović-Šmalc V, Bidzan L, Emin Ceylan M, Schreiner A. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol. 2013;3:191-199.
33. Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013;12:22.
34. McGorry PD, Purcell R, Goldstone S, Amminger GP. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr Opin Psychiatry. 2011;24:301-306.
35. Steinwachs DM, Roter DL, Skinner EA, et al. A web-based program to empower patients who have schizophrenia to discuss quality of care with mental health providers. Psychiatr Serv. 2011;62:1296-1302.
36. Spaniel F, Vohlídka P, Hrdlicka J, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res. 2008;98:312-317.
37. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70:1397-1406.
38. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Maintenance treatment with longacting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. J Clin Psychiatry. 2012;73:1224-1233.
39. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.